U.S. FDA approves Pfizer drug for menopause symptoms
(Reuters) - U.S. health regulators approved Pfizer Inc's menopause drug Duavee, which the company hopes will reduce hot flashes with fewer side effects than older hormone-replacement therapies.
The Food and Drug Administration said on Thursday it approved the drug to treat women with moderate to severe menopause symptoms and to prevent post-menopausal osteoporosis, a bone disease which can increase the risk of fractures.
The drug, which Pfizer is developing with Ligand Pharmaceuticals Inc, combines bazedoxifene - which belongs to a class of drugs known as selective estrogen receptor modulators, or SERMS - and conjugated estrogens, which are derived from the urine of pregnant horses and contained in Pfizer's menopause drug Premarin.
(Reporting by Toni Clarke in Washington; Editing by Gerald E. McCormick)
- Divided, Scots prepare to vote on fate of the United Kingdom |
- Australian PM says police raids follow threat of beheading
- Apple to unveil new iPads, operating system on Oct. 21: report
- IMF warns of risks from 'excessive' financial market bets
- Dollar soars to six-year peak on yen after Fed, Tokyo stocks cheer
Major U.S. poultry firms are administering antibiotics to their flocks far more pervasively than regulators realize, posing a potential risk to human health. Full Article